keyword
https://read.qxmd.com/read/38700450/prostate-specific-membrane-antigen-targeted-starpeg-nanocarrier-for-imaging-and-therapy-of-prostate-cancer
#1
JOURNAL ARTICLE
Niranjan Meher, Gary W Ashley, Kondapa Naidu Bobba, Anju Wadhwa, Anil P Bidkar, Chandrashekhar Dasari, Changhua Mu, Ramya Ambur Sankaranarayanan, Juan A Camara Serrano, Athira Raveendran, David P Bulkley, Rahul Aggarwal, Nancy Y Greenland, Adam Oskowitz, David M Wilson, Youngho Seo, Daniel V Santi, Henry F VanBrocklin, Robert R Flavell
BACKGROUND: The uptake of large (>10 nm) non-targeted nanocarriers by bulk tumors is thought to be dominated by passive extravasation through porous tumor vessels and limited lymphatic drainage, the enhanced permeability and retention (EPR) effect. Prior studies demonstrated radiolabeled tumor-targeted and non-targeted 4-arm 40 kDa star polyethylene glycol (StarPEG) polymers for cancer imaging. By adding small molecule ligands targeting prostate-specific membrane antigen (PSMA) to the StarPEG polymer, marked increase in tumor uptake, penetration and retention in the tumor core was observed...
May 3, 2024: Advanced Healthcare Materials
https://read.qxmd.com/read/38699639/nanocage-incorporated-engineered-destabilized-3-utr-are-of-erbb2-inhibits-tumor-growth-and-liver-and-lung-metastasis-in-egfr-t790m-osimertinib-and-trastuzumab-resistant-and-erbb2-expressing-nsclc-via-the-reduction-of-erbb2
#2
JOURNAL ARTICLE
Chidiebere U Awah, Joo Sun Mun, Aloka Paragodaarachchi, Baris Boylu, Martin Nzegwu, Hiroshi Matsui, Olorunseun Ogunwobi
Non-small cell lung cancer (NSCLC) caused more deaths in 2017 than breast cancer, prostate, and brain cancers combined. This is primarily due to their aggressive metastatic nature, leading to more fatal rates of cancer patients. Despite this condition, there are no clinically approved drugs that can target metastasis. The NSCLC with EGFR T790M-overexpressing HER2 shows the resistance to osimertinib and trastuzumab starting 10-18 months after the therapy, and thus prospects are grim to these patients. To target the recalcitrant ERBB2 driver oncogene, we developed two engineered destabilizing 3'UTR ERBB2 constructs that degrade the endogenous ERBB2 transcript and proteins by overwriting the encoded endogenous ERBB2 mRNA with the destabilizing message...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38693424/long-non-coding-rna-loxl1-as1-a-potential-biomarker-and-therapeutic-target-in-human-malignant-tumors
#3
REVIEW
Xiao-Ping Fu, Chun-Yan Ji, Wen-Qian Tang, Ting-Ting Yu, Lei Luo
Long non-coding RNAs (lncRNAs) are transcripts that contain more than 200 nucleotides. Despite their inability to code proteins, multiple studies have identified their important role in human cancer through different mechanisms. LncRNA lysyl oxidase like 1 antisense RNA 1 (LOXL1-AS1), a newly discovered lncRNA located on human chromosome 15q24.1, has recently been shown to be involved in the occurrence and progression of various malignancies, such as colorectal cancer, gastric cancer, hepatocellular carcinoma, prostate cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, breast cancer, glioma, thymic carcinoma, pancreatic carcinoma...
May 2, 2024: Clinical and Experimental Medicine
https://read.qxmd.com/read/38693090/cell-electrokinetic-fingerprint-a-novel-approach-based-on-optically-induced-dielectrophoresis-odep-for-in-flow-identification-of-single-cells
#4
JOURNAL ARTICLE
Joanna Filippi, Paola Casti, Gianni Antonelli, Michela Murdocca, Arianna Mencattini, Francesca Corsi, Michele D'Orazio, Alessandro Pecora, Massimiliano De Luca, Giorgia Curci, Lina Ghibelli, Federica Sangiuolo, Steven L Neale, Eugenio Martinelli
A novel optically induced dielectrophoresis (ODEP) system that can operate under flow conditions is designed for automatic trapping of cells and subsequent induction of 2D multi-frequency cell trajectories. Like in a "ping-pong" match, two virtual electrode barriers operate in an alternate mode with varying frequencies of the input voltage. The so-derived cell motions are characterized via time-lapse microscopy, cell tracking, and state-of-the-art machine learning algorithms, like the wavelet scattering transform (WST)...
May 1, 2024: Small Methods
https://read.qxmd.com/read/38691812/trial-of-electronic-medical-record-integrated-next-generation-sequencing-ordering-in-veterans-affairs-cancer-care
#5
JOURNAL ARTICLE
James H Stoeckle, Sarah G Poland, Hannah Maynard, Stefanie D Roman, Daniel Mettman, Danil V Makarov, Scott Sherman, Daniel J Becker
PURPOSE: Previous studies document underuse of next-generation sequencing (NGS). We examined the impact to oncology care for veterans of incorporating NGS ordering into the Veterans Affairs (VA) electronic medical record (EMR) at two New York City VA Medical Centers. METHODS: We identified patients with non-small cell lung cancer and prostate cancer with oncology clinic visits and NGS testing indications between January and December 2021. Patients were divided into external ordering (EO) with visits before we implemented an EMR ordering system for NGS in July 2021, and internal ordering (IO) with visits after this date...
April 2024: JCO Precision Oncology
https://read.qxmd.com/read/38672614/lysine-methyltransferase-9-kmt9-is-an-actionable-target-in-muscle-invasive-bladder-cancer
#6
JOURNAL ARTICLE
Sainab Totonji, Anna Ramos-Triguero, Dominica Willmann, Manuela Sum, Sylvia Urban, Helena Bauer, Astrid Rieder, Sheng Wang, Holger Greschik, Eric Metzger, Roland Schüle
Novel treatment modalities are imperative for the challenging management of muscle-invasive and metastatic BC to improve patient survival rates. The recently identified KMT9, an obligate heterodimer composed of KMT9α and KMT9β, regulates the growth of various types of tumors such as prostate, lung, and colon cancer. While the overexpression of KMT9α was previously observed to be associated with aggressive basal-like MIBC in an analysis of patients' tissue samples, a potential functional role of KMT9 in this type of cancer has not been investigated to date...
April 17, 2024: Cancers
https://read.qxmd.com/read/38672601/contrast-agent-dynamics-determine-radiomics-profiles-in-oncologic-imaging
#7
JOURNAL ARTICLE
Martin L Watzenboeck, Lucian Beer, Daria Kifjak, Sebastian Röhrich, Benedikt H Heidinger, Florian Prayer, Ruxandra-Iulia Milos, Paul Apfaltrer, Georg Langs, Pascal A T Baltzer, Helmut Prosch
BACKGROUND: The reproducibility of radiomics features extracted from CT and MRI examinations depends on several physiological and technical factors. The aim was to evaluate the impact of contrast agent timing on the stability of radiomics features using dynamic contrast-enhanced perfusion CT (dceCT) or MRI (dceMRI) in prostate and lung cancers. METHODS: Radiomics features were extracted from dceCT or dceMRI images in patients with biopsy-proven peripheral prostate cancer (pzPC) or biopsy-proven non-small cell lung cancer (NSCLC), respectively...
April 16, 2024: Cancers
https://read.qxmd.com/read/38667288/development-and-characterisation-of-a-new-patient-derived-xenograft-model-of-ar-negative-metastatic-castration-resistant-prostate-cancer
#8
JOURNAL ARTICLE
Daniel J Turnham, Manisha S Mullen, Nicholas P Bullock, Kathryn L Gilroy, Anna E Richards, Radhika Patel, Marcos Quintela, Valerie S Meniel, Gillian Seaton, Howard Kynaston, Richard W E Clarkson, Toby J Phesse, Peter S Nelson, Michael C Haffner, John N Staffurth, Helen B Pearson
As the treatment landscape for prostate cancer gradually evolves, the frequency of treatment-induced neuroendocrine prostate cancer (NEPC) and double-negative prostate cancer (DNPC) that is deficient for androgen receptor (AR) and neuroendocrine (NE) markers has increased. These prostate cancer subtypes are typically refractory to AR-directed therapies and exhibit poor clinical outcomes. Only a small range of NEPC/DNPC models exist, limiting our molecular understanding of this disease and hindering our ability to perform preclinical trials exploring novel therapies to treat NEPC/DNPC that are urgently needed in the clinic...
April 12, 2024: Cells
https://read.qxmd.com/read/38663125/adherence-to-the-low-fat-diet-pattern-reduces-the-risk-of-lung-cancer-in-american-adults-aged-55-years-and-above-a-prospective-cohort-study
#9
JOURNAL ARTICLE
Linglong Peng, Qingqing Du, Ling Xiang, Haitao Gu, Haoyun Luo, Zhiquan Xu, Hongmei He, Boning Xia, Zhihang Zhou, Yaxu Wang, Ying Chen
OBJECTIVES: There is little evidence on the association between low-fat dietary patterns and lung cancer risk among middle-aged and older adults. To fill this gap, we comprehensively investigated the association of adherence to a low-fat diet (LFD) and intake of different fat components including saturated, monounsaturated, and polyunsaturated fatty acids with incidence of lung cancer and its subtypes [non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)] among adults aged 55 years and older...
April 24, 2024: Journal of Nutrition, Health & Aging
https://read.qxmd.com/read/38662054/comparing-symptom-clusters-in-cancer-survivors-by-cancer-diagnosis-a-latent-class-profile-analysis
#10
COMPARATIVE STUDY
Lena J Lee, Claire J Han, Leorey Saligan, Gwenyth R Wallen
PURPOSE: Research on symptom clusters in oncology is progressing, but knowledge gaps remain. One question is whether the number and types of symptom subgroups (i.e., latent classes) differ based on cancer diagnosis. The purpose of this study was to: (1) identify and compare latent class subgroups based on four highly prevalent symptoms (pain, fatigue, sleep disturbance, and depression), and (2) examine the differences in sociodemographic and clinical factors in the identified latent classes across the seven cancer types (i...
April 25, 2024: Supportive Care in Cancer
https://read.qxmd.com/read/38659592/discovery-of-a-novel-natural-compound-vitekwangin-b-with-ano1-protein-reduction-properties-and-anticancer-potential
#11
JOURNAL ARTICLE
Yohan Seo, Sion Lee, Minuk Kim, Dongguk Kim, Sung Baek Jeong, Raju Das, Armin Sultana, SeonJu Park, Nguyen Xuan Nhiem, Phan Thi Thanh Huong, Oh-Bin Kwon, Wan Namkung, Joohan Woo
Background: Prostate cancer and non-small cell lung cancer (NSCLC) present significant challenges in the development of effective therapeutic strategies. Hormone therapies for prostate cancer target androgen receptors and prostate-specific antigen markers. However, treatment options for prostatic small-cell neuroendocrine carcinoma are limited. NSCLC, on the other hand, is primarily treated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors but exhibits resistance. This study explored a novel therapeutic approach by investigating the potential anticancer properties of vitekwangin B, a natural compound derived from Vitex trifolia ...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38658552/high-clonal-diversity-and-spatial-genetic-admixture-in-early-prostate-cancer-and-surrounding-normal-tissue
#12
JOURNAL ARTICLE
Ning Zhang, Luuk Harbers, Michele Simonetti, Constantin Diekmann, Quentin Verron, Enrico Berrino, Sara E Bellomo, Gabriel M C Longo, Michael Ratz, Niklas Schultz, Firas Tarish, Peng Su, Bo Han, Wanzhong Wang, Sofia Onorato, Dora Grassini, Roberto Ballarino, Silvia Giordano, Qifeng Yang, Anna Sapino, Jonas Frisén, Kanar Alkass, Henrik Druid, Vassilis Roukos, Thomas Helleday, Caterina Marchiò, Magda Bienko, Nicola Crosetto
Somatic copy number alterations (SCNAs) are pervasive in advanced human cancers, but their prevalence and spatial distribution in early-stage, localized tumors and their surrounding normal tissues are poorly characterized. Here, we perform multi-region, single-cell DNA sequencing to characterize the SCNA landscape across tumor-rich and normal tissue in two male patients with localized prostate cancer. We identify two distinct karyotypes: 'pseudo-diploid' cells harboring few SCNAs and highly aneuploid cells...
April 24, 2024: Nature Communications
https://read.qxmd.com/read/38650632/activation-of-p53-signaling-and-regression-of-breast-and-prostate-carcinoma-cells-by-spirooxindole-benzimidazole-small-molecules
#13
JOURNAL ARTICLE
Assem Barakat, Saeed Alshahrani, Abdullah Mohammed Al-Majid, Abdullah Saleh Alamary, Matti Haukka, Marwa M Abu-Serie, Alexander Dömling, Luis R Domingo, Yaseen A M M Elshaier
This study discusses the synthesis and use of a new library of spirooxindole-benzimidazole compounds as inhibitors of the signal transducer and activator of p53, a protein involved in regulating cell growth and cancer prevention. The text includes the scientific details of the [3 + 2] cycloaddition (32CA) reaction between azomethine ylide 7a and ethylene 3a within the framework of Molecular Electron Density Theory. The mechanism of the 32CA reaction proceeds through a two-stage one-step process, with emphasis on the highly asynchronous transition state structure...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38648995/systematic-review-of-the-efficacy-of-stereotactic-ablative-radiotherapy-for-oligoprogressive-disease-in-metastatic-cancer
#14
REVIEW
Emma Doyle, Angus J Killean, Stephen Harrow, Iain D Phillips
BACKGROUND: Stereotactic Ablative Radiotherapy (SABR) for the treatment of oligometastatic disease can improve survival and delay the requirement for systemic therapy. The benefits of SABR in oligoprogressive disease are less well-defined. Here, we evaluate the available evidence investigating the efficacy of SABR in the treatment of oligoprogressive disease. METHODS: A systematic review was carried out following PRISMA guidelines. Medline and Embase databases were searched using the terms "stereotactic radiotherapy" OR "SABR" OR "Stereotactic Ablative Body Radiotherapy" OR "SBRT" OR "SRT" AND "oligoprogression" in May 2022, June 2023, and February 2024...
April 20, 2024: Radiotherapy and Oncology
https://read.qxmd.com/read/38645232/pgc-1%C3%AE-drives-small-cell-neuroendocrine-cancer-progression-towards-an-ascl1-expressing-subtype-with-increased-mitochondrial-capacity
#15
Grigor Varuzhanyan, Chia-Chun Chen, Jack Freeland, Tian He, Wendy Tran, Kai Song, Liang Wang, Donghui Cheng, Shili Xu, Gabriella A Dibernardo, Favour N Esedebe, Evan R Abt, Jung Wook Park, Sanaz Memarzadeh, Thomas Graeber, Orian Shirihai, Owen Witte
Adenocarcinomas from multiple tissues can converge to treatment-resistant small cell neuroendocrine (SCN) cancers comprised of ASCL1, POU2F3, NEUROD1, and YAP1 subtypes. We investigated how mitochondrial metabolism influences SCN cancer (SCNC) progression. Extensive bioinformatics analyses encompassing thousands of patient tumors and human cancer cell lines uncovered enhanced expression of PGC-1α, a potent regulator of mitochondrial oxidative phosphorylation (OXPHOS), across several SCNC types. PGC-1α correlated tightly with increased expression of the lineage marker ASCL1 through a positive feedback mechanism...
April 13, 2024: bioRxiv
https://read.qxmd.com/read/38645136/collateral-damage-of-nudt15-deficiency-in-cancer-provides-a-cancer-pharmacogenetic-therapeutic-window-with-thiopurines
#16
Jacob C Massey, Joseph Magagnoli, S Scott Sutton, Phillip J Buckhaults, Michael D Wyatt
Genome instability is a hallmark of cancer and are driven by mutations in oncogenes and tumor suppressor genes. Despite successes seen with select targeted therapeutics, this type of personalized medicine is only beneficial for a small subpopulation of cancer patients who have one of a few actionable genetic changes. Most tumors also contain hundreds of passenger mutations that offered no fitness advantage or disadvantage during tumor evolution. Mutations in known pharmacogenetic (PGx) loci for which germline variants encode variability in drug response can cause somatically acquired drug sensitivity...
April 11, 2024: bioRxiv
https://read.qxmd.com/read/38645034/single-cell-analysis-of-treatment-resistant-prostate-cancer-implications-of-cell-state-changes-for-cell-surface-antigen-targeted-therapies
#17
Samir Zaidi, Jooyoung Park, Joseph M Chan, Martine P Roudier, Jimmy L Zhao, Anuradha Gopalan, Kristine M Wadosky, Radhika A Patel, Erolcan Sayar, Wouter R Karthaus, D Henry Kates, Ojasvi Chaudhary, Tianhao Xu, Ignas Masilionis, Linas Mazutis, Ronan Chaligné, Aleksandar Obradovic, Irina Linkov, Afsar Barlas, Achim Jungbluth, Natasha Rekhtman, Joachim Silber, Katia Manova-Todorova, Philip A Watson, Lawrence D True, Colm M Morrissey, Howard I Scher, Dana Rathkopf, Michael J Morris, David W Goodrich, Jungmin Choi, Peter S Nelson, Michael C Haffner, Charles L Sawyers
UNLABELLED: Targeting cell surface molecules using radioligand and antibody-based therapies has yielded considerable success across cancers. However, it remains unclear how the expression of putative lineage markers, particularly cell surface molecules, varies in the process of lineage plasticity, wherein tumor cells alter their identity and acquire new oncogenic properties. A notable example of lineage plasticity is the transformation of prostate adenocarcinoma (PRAD) to neuroendocrine prostate cancer (NEPC)--a growing resistance mechanism that results in the loss of responsiveness to androgen blockade and portends dismal patient survival...
April 12, 2024: bioRxiv
https://read.qxmd.com/read/38644246/-construction-of-a-model-based-on-multipoint-full-layer-puncture-biopsy-for-predicting-pathological-complete-response-after-neoadjuvant-therapy-for-locally-advanced-rectal-cancer
#18
JOURNAL ARTICLE
Y Jin, Z W Zhai, L T Sun, P D Xia, H Hu, C Q Jiang, B C Zhao, H Qu, Q Qian, Y Dai, H W Yao, Z J Wang, J G Han
Objective: To investigate the value of transanal multipoint full-layer puncture biopsy (TMFP) in predicting pathological complete response (pCR) after neoadjuvant radiotherapy and chemotherapy (nCRT) in patients with locally advanced rectal cancer (LARC) and to establish a predictive model for providing clinical guidance regarding the treatment of LARC. Methods: In this multicenter, prospective, cohort study, we collected data on 110 LARC patients from four hospitals between April 2020 and March 2023: Beijing Chaoyang Hospital of Capital Medical University (50 patients), Beijing Friendship Hospital of Capital Medical University (41 patients), Qilu Hospital of Shandong University (16 patients), and Zhongnan Hospital of Wuhan University (three patients)...
April 25, 2024: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://read.qxmd.com/read/38641298/androgen-receptor-and-estrogen-receptor-variants-in-prostate-and-breast-cancers
#19
JOURNAL ARTICLE
José C Valentín López, Carol A Lange, Scott M Dehm
The androgen receptor (AR) and estrogen receptor alpha (ERα) are steroid receptor transcription factors with critical roles in the development and progression of prostate and breast cancers. Advances in the understanding of mechanisms underlying the ligand-dependent activation of these transcription factors have contributed to the development of small molecule inhibitors that block AR and ERα actions. These inhibitors include competitive antagonists and degraders that directly bind the ligand binding domains of these receptors, luteinizing hormone releasing hormone (LHRH) analogs that suppress gonadal synthesis of testosterone or estrogen, and drugs that block specific enzymes required for biosynthesis of testosterone or estrogen...
April 17, 2024: Journal of Steroid Biochemistry and Molecular Biology
https://read.qxmd.com/read/38637140/a-systematic-review-on-the-diagnostic-value-of-fibroblast-activation-protein-inhibitor-pet-ct-in-genitourinary-cancers
#20
JOURNAL ARTICLE
Marinus J Hagens, Pim J van Leeuwen, Maurits Wondergem, Thierry N Boellaard, Francesco Sanguedolce, Daniela E Oprea-Lager, Axel Bex, André N Vis, Henk G van der Poel, Laura S Mertens
In contemporary oncologic diagnostics, molecular imaging modalities are pivotal for precise local and metastatic staging. Recent studies identified fibroblast activation protein as a promising target for molecular imaging across various malignancies. Therefore, we aimed to systematically evaluate the current literature on the utility of fibroblast activation protein inhibitor (FAPI) PET/CT for staging patients with genitourinary malignancies. Methods: A systematic Embase and Medline search was conducted, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) process, on August 1, 2023...
April 18, 2024: Journal of Nuclear Medicine
keyword
keyword
110964
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.